Visceral Sensitivity in IBD (Irritable Bowel Disease) and IBS (Irritable Bowel Syndrome)

Overview

Aim

More insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.

Description

Methods

Sample collection in healthy subjects, IBD and IBS patients:

• biopsy of rectum and colon descendens
• blood sample collection
• collection of sample of nasal mucosa
• feces collection
• questionnaires
• rectal barostat sensitivity measurement
• transit measurement of colon
• MR scan of brain

Eligibility

Inclusion Criteria:

For group 1: IBS

1. Irritable Bowel Syndrome (IBS) (ROME III criteria)
2. No obvious organic explanation for the IBS symptoms
3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study

        Group 2: active ulcerative colitis 1. diagnosis of ulcerative colitis (Confirmed by at
        least one sigmoidoscopy) 3. Medication which affects the gastrointestinal motility or
        perception should be stopped at least 24 hours before the study
        Group 3: ulcerative colitis in remission (3a: with IBS symptoms, 3b: without IBS symptoms)
          1. diagnosis of ulcerative colitis (Confirmed by at least one sigmoidoscopy)
          2. remission is confirmed by at least one sigmoidoscopy
          3. Medication which affects the gastrointestinal motility or perception should be stopped
             at least 24 hours before the study
             Only for group 3a:
          4. Rome III criteria for IBS
        Group 4: Healthy controls No abdominal (pain) complaints.
        Group 5: active Crohn's disease
        1. diagnosis of Crohn's disease (Confirmed by at least one sigmoidoscopy) 3. Medication
        which affects the gastrointestinal motility or perception should be stopped at least 24
        hours before the study
        Group 6: Crohn's disease in remission (6a: with IBS symptoms, 6b: without IBS symptoms)
          1. diagnosis of Crohn's disease (Confirmed by at least one sigmoidoscopy)
          2. remission is confirmed by at least one sigmoidoscopy
          3. Medication which affects the gastrointestinal motility or perception should be stopped
             at least 24 hours before the study
        Exclusion Criteria:
        For all groups:
          1. co-morbidity: severe kidney- and/or liver disease or thyroid abnormalities and
             impaired clotting
          2. Abdominal chirurgy (except for an uncomplicated appendectomy)